The Manufacturers Life Insurance Company Increases Stock Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

The Manufacturers Life Insurance Company grew its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 4.1% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 143,431 shares of the biopharmaceutical company’s stock after acquiring an additional 5,587 shares during the period. The Manufacturers Life Insurance Company owned about 0.25% of Agios Pharmaceuticals worth $6,373,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Caxton Associates LP boosted its holdings in Agios Pharmaceuticals by 0.7% during the 2nd quarter. Caxton Associates LP now owns 37,453 shares of the biopharmaceutical company’s stock valued at $1,615,000 after acquiring an additional 264 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Agios Pharmaceuticals by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 363 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in Agios Pharmaceuticals during the 2nd quarter worth approximately $37,000. Quest Partners LLC acquired a new stake in Agios Pharmaceuticals during the 2nd quarter worth approximately $40,000. Finally, Federated Hermes Inc. boosted its position in Agios Pharmaceuticals by 9.0% in the 2nd quarter. Federated Hermes Inc. now owns 13,394 shares of the biopharmaceutical company’s stock valued at $578,000 after buying an additional 1,108 shares during the period.

Insider Buying and Selling at Agios Pharmaceuticals

In related news, CFO Cecilia Jones sold 2,542 shares of the stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the sale, the chief financial officer now owns 20,158 shares of the company’s stock, valued at $988,346.74. This trade represents a 11.20 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 4.93% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on AGIO. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Friday, September 20th. Scotiabank upped their price target on Agios Pharmaceuticals from $51.00 to $53.00 and gave the stock a “sector outperform” rating in a report on Friday, November 1st. StockNews.com upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 9th. Leerink Partners lowered shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $60.00 to $56.00 in a research note on Friday, September 27th. Finally, Raymond James reaffirmed an “outperform” rating and issued a $51.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Agios Pharmaceuticals currently has an average rating of “Hold” and an average target price of $52.33.

Agios Pharmaceuticals Stock Down 0.8 %

Shares of AGIO stock opened at $58.97 on Friday. The stock has a market cap of $3.36 billion, a P/E ratio of 5.23 and a beta of 0.80. Agios Pharmaceuticals, Inc. has a fifty-two week low of $20.96 and a fifty-two week high of $62.58. The business has a fifty day simple moving average of $49.39 and a 200-day simple moving average of $45.99.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.